On August 4, 2026, Puerto Rico’s governor signed Executive Order 2026-037: a Department of Health–led assessment toward a Pilot Clinical Research Program for Emerging Therapies, with ibogaine, psilocybin, and MDMA named. The work is infrastructure and a scientific committee — not licensed mushroom services, not a take-home protocol, and not a waiver of FDA or DEA rules. Veterans are a priority population for possible trial participation, not an open enrollment list.
What the order actually does
EO 2026-037 tells Puerto Rico’s health department to assess whether the island can host rigorous, federally compatible clinical trials of investigational therapies — including ibogaine, psilocybin, and MDMA. It is a planning order, not a treatment program.
Governor Jenniffer González-Colón signed the order on August 4, 2026, at La Fortaleza. The public case is familiar: severe mental illness, neurodegenerative disease, and substance-use disorders where existing care often falls short. The instrument is an executive order, not a statute and not an FDA application.
The Department of Health is directed to build the scientific, regulatory, and operational case for a “Pilot Clinical Research Program for Emerging Therapies.” That means evidence review, ethics, logistics, workforce, and whether Puerto Rico’s hospitals and universities can actually run multicenter trials under state and federal rules.
Jack Gorsline’s reporting for DoubleBlind (August 14, 2026) is the news account we are working from: https://doubleblindmag.com/puerto-rico-makes-moves-on-ibogaine-mdma-and-psilocybin/
The order, as reported, also says the quiet part out loud: it does not authorize widespread or routine clinical use of ibogaine, psilocybin, MDMA, or other investigational compounds. Readiness first. Treatment later, if the science and the regulators allow it.
Ibogaine, MDMA, and psilocybin are not interchangeable
The order names three different molecules with different risk profiles. Ibogaine is being discussed mainly for severe addiction; MDMA and psilocybin for mental-health indications. None of them is a legal wellness service in Puerto Rico because of this signature.
Ibogaine is a psychoactive alkaloid from Tabernanthe iboga, studied as a possible interruption for severe opioid and other substance-use addictions. It is not a mushroom, and it is not a casual substitute for an Oregon service-center session. Cardiac screening is a live clinical issue in the ibogaine literature. An executive order does not make that risk disappear.
MDMA-assisted therapy and synthetic psilocybin (the COMP360-class product, not a bag of cubensis) sit in different FDA-track programs. Puerto Rico’s order is about whether the island can host trials, not about copying Oregon’s Measure 109 or Colorado’s healing centers onto a U.S. territory.
If you want the supervised, state-licensed mushroom path that already exists, that is still Oregon and Colorado: /legal-status/oregon and /legal-status/colorado. Territory research infrastructure is a different stack: IRB, federal IND, DEA Schedule I handling, and a clinic that can run a protocol.
For how clinical psilocybin is actually used in trials, see /guides/psilocybin-therapy and /for/treatment-resistant-depression.
Veterans are named. That is not the same as access.
The Health Department must coordinate with the Office of the Puerto Rico Veterans Advocate on education and possible trial participation. Eligibility, evidence, and federal authorizations still gate every seat.
The order instructs coordination so veterans can learn about — and, if authorized, enter — clinical trials. That is a priority flag, not a VA clinic opening next month and not a walk-in ibogaine program.
Federally, the VA is already running its own psilocybin work. In August 2026 the Department of Veterans Affairs announced PIVOT, a five-site trial of investigational psilocybin for treatment-resistant depression in veterans, including people with concurrent PTSD. That study uses pharmaceutical-grade COMP360, FDA-aligned safety protocols, and psychological support. It is registered as NCT07226232.
VA announcement: https://news.va.gov/press-room/va-launches-psilocybin-trial-for-veterans-with-treatment-resistant-depression/
Compass Pathways on the same collaboration: https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Working-with-U-S--Department-of-Veterans-Affairs-for-Investigational-Study-of-Psilocybin/default.aspx
Puerto Rico’s order can point veterans toward research. It cannot, by itself, reschedule psilocybin or stand up a COMP360 site. The VA’s own release also says veterans should not replace existing mental-health care with unprescribed psychedelics.
Condition pages: /conditions/depression, /conditions/ptsd, /conditions/addiction.
A committee, a report, then a political decision
A Scientific and Regulatory Advisory Committee inside the Department of Health will evaluate evidence, viability, and infrastructure, then report. The governor decides the next policy step. No launch date is in the order.
Members are to be appointed by the governor from clinical research, public health, bioethics, pharmacology, neurology, psychiatry, psychology, and regulatory affairs. Their job is not to cheerlead. It is to say whether a pilot is scientifically, ethically, clinically, and financially viable — and what the island would have to upgrade.
Advocates on the island, including the Colectivo Psicodélico de Puerto Rico, have treated the signature as a signal that San Juan is finally tracking the global evidence base. That is fair as politics. It is not the same as a protocol, a pharmacy, or a facilitator license.
The reporting also notes the governor’s own political weather: a halted election-fraud investigation involving her 2024 campaign, as covered by ProPublica. We are not litigating that here. We are noting that a research executive order can be both a real health-policy instrument and a document signed in a noisy news cycle. Read the committee’s report when it exists. Do not treat the signing ceremony as the result.
Puerto Rico’s $50 billion pharmaceutical manufacturing footprint is the industrial argument in the order: the island already makes devices and drugs at scale. Manufacturing insulin pumps is not the same skill as running a Schedule I psychedelic trial. The committee is supposed to say how wide that gap is.
PsyBear takeaways
Treat EO 2026-037 as a research-readiness order. If you need care this year, this document is not your access path. If you are watching where trials might land, Puerto Rico just put itself on the list.
1. Research ≠ access. The order is explicit: no routine clinical use. Anyone selling “Puerto Rico legalized ibogaine” from this headline is wrong.
2. Three molecules, three risk files. Do not collapse ibogaine, MDMA, and psilocybin into one “psychedelic therapy” product. Cardiac risk, psychotherapy models, and federal trial designs do not travel together.
3. Veterans deserve trials with containers, not underground promises. The VA PIVOT study is the current federal example of how that is supposed to look: screened, two-dose, supported. Puerto Rico’s veteran language should be read against that standard, not against a retreat brochure.
4. Oregon and Colorado remain the licensed mushroom services. Territory executive orders do not create Measure 109. Map: /legal-status
5. Watch the committee report, not the podium. The next fact that matters is whether Health can staff the advisory body and what it actually recommends.
Psilocybin, MDMA, and ibogaine remain controlled substances under U.S. federal law outside authorized research and, for psilocybin, licensed state programs. This article is education and commentary, not medical advice and not an invitation to seek unregulated treatment in Puerto Rico or anywhere else.
Key Takeaways
On August 4, 2026, Puerto Rico’s governor signed Executive Order 2026-037: a Department of Health–led assessment toward a Pilot Clinical Research Program for Emerging Therapies, with ibogaine, psilocybin, and MDMA named. The work is infrastructure and a scientific committee — not licensed mushroom services, not a take-home protocol, and not a waiver of FDA or DEA rules. Veterans are a priority population for possible trial participation, not an open enrollment list.
FAQ
- Did Puerto Rico legalize psilocybin, MDMA, or ibogaine?
- No. Executive Order 2026-037 directs a health-department assessment toward a possible clinical-research pilot. As reported, it does not authorize routine clinical use of those investigational compounds.
- What is Puerto Rico Executive Order 2026-037?
- A August 4, 2026 order by Gov. Jenniffer González-Colón creating work toward a Pilot Clinical Research Program for Emerging Therapies, with a scientific advisory committee inside the Department of Health. Ibogaine, psilocybin, and MDMA are named as examples of compounds that might be studied.
- Can veterans in Puerto Rico get psychedelic therapy now?
- Not from this order. The Health Department is told to coordinate education and explore trial participation with the Veterans Advocate, under eligibility rules and federal authorizations. Separately, the U.S. VA announced the PIVOT psilocybin trial at five VA medical centers in August 2026.
- Is this the same as Oregon or Colorado psilocybin services?
- No. Oregon and Colorado license supervised sessions with natural mushrooms. Puerto Rico’s order is about whether the territory can host FDA-compatible clinical trials of investigational drugs.